Form 4: Katharine Knobil Reports Stock Option Grant in Pliant Therapeutics

Director Katharine Knobil reports acquisition of stock options in Pliant Therapeutics.

Summary

• Katharine Knobil, a director of Pliant Therapeutics, reported a transaction on June 13, 2024.
• She acquired options to buy 26,764 shares of common stock at an exercise price of $13.06.
• These options vest quarterly, with 25% vesting each quarter for the first three quarters after the grant date.
• The remaining 25% vests on the earlier of the one-year anniversary of the grant date or the next annual meeting, contingent on continued service as a director.
• Following the transaction, Knobil beneficially owns 26,764 shares of common stock directly.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. The grant of options is generally a positive sign, aligning director interests with shareholders, but it's a routine event.

Positives

• The grant of stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies to ensure transparency and compliance with securities regulations.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates